McCafferty GP, Misajet BA, Laping NJ, Edwards RM, Thorneloe KS. Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice. Am J Physiol Renal Physiol 295: F507-F514, 2008. First published May 28, 2008 doi:10.1152/ajprenal.00054.2008.-Nonsteroidal anti-inflammatory cyclooxygenase inhibitors that function to reduce prostaglandin E2 (PGE2) production have been widely reported as effective agents in models of urinary bladder overactivity. We therefore investigated a potential role for the PGE2 receptor, EP3, in urinary bladder function by performing conscious, freely moving cystometry on EP3 receptor knockout (KO) mice. EP3 KO mice demonstrated an enhanced bladder capacity compared with wild-type (WT) mice (ϳ185% of WT) under control conditions, based on larger voided and infused bladder volumes. Infusion of the EP3 receptor agonist GR63799X into the bladder of WT mice reduced the bladder capacity. This was ineffective in EP3 KO mice that demonstrated a time-dependent increase in bladder capacity with GR63799X, an effect similar to that observed with vehicle in both genotypes. In addition, infusion of PGE2 into WT mice induced bladder overactivity, an effect that was significantly blunted in the EP3 KO mice. The data reported here provide the first evidence supporting a functional role for EP3 receptors in normal urinary bladder function and implicate EP3 as a contributor to bladder overactivity during pathological conditions of enhanced PGE2 production, as reported previously in overactive bladder patients. GR63799X; conscious cystometry CYCLOOXYGENASE (COX) inhibitors, nonsteroidal anti-inflammatory drugs, are widely utilized to treat pain, targeting both constitutively expressed COX-1 and/or inducible COX-2 isoforms (6). This is based on a large body of evidence that COX-2 expression is increased in response to cytokines, injury, and inflammation (3). COX-2 expression is also enhanced in preclinical models of urinary bladder dysfunction, including bladder outlet obstruction and interstitial cystitis (11, 24, 25) . Consistent with this finding, COX inhibitors have demonstrated in vivo efficacy in bladder overactivity models performed in multiple species (1, 11, 13, 32, 36) . COX inhibitors have also been evaluated in small clinical voiding studies yielding positive outcomes (2, 4, 27) .
stretch (24, 25) and electrical field stimulation (7) . The bladder urothelium also releases PGE 2 in a stretch-dependent manner (19, 26) , an effect potentiated in spinal cord-injured rats that present with bladder overactivity and increased PGE 2 levels in their urine (19) . PGE 2 contracts isolated bladder strips in vitro (23, 26) and evokes bladder overactivity in vivo when infused intravesicularly into bladders of rats and mice via a mechanism involving capsaicin-sensitive sensory bladder afferents (12, 17, 18, 29) . Likewise, intravesicular PGE 2 and sulprostone, an EP1/ EP3 agonist, induce bladder instability and reduce bladder capacity in humans (30) . As PGE 2 is enhanced in the urine of male and female overactive bladder patients (14, 15) and in preclinical models (11, 24, 25) , PGE 2 likely contributes to the clinical pathophysiology of bladder overactivity. Taken together, the literature suggests a role for PGE 2 in multiple aspects of urinary bladder physiology/pathophysiology in numerous species. PGE 2 mediates its effects by activating the EP family of G protein-coupled receptors that consist of four known isoforms, EP1-EP4 (9) . Of these, it has been previously suggested that EP1 receptors are involved in PGE 2 -induced bladder overactivity and bladder outlet obstruction (16, 18, 29) . Here, we investigated a potential role for the EP3 receptor isoform in urinary bladder function by characterizing the urodynamics and pharmacological responses of EP3 knockout (KO) mice.
MATERIALS AND METHODS
Mice. The generation of the EP3 receptor KO mouse was described previously (8) . The EP3 KO allele was bred into 129P3/J and B6 backgrounds and maintained as intercrossed homozygous colonies at Jackson Labs. Wild-type (WT) mice were also obtained from Jackson Labs 129P3/J and C57Bl/6J colonies. All experimental procedures were approved by GlaxoSmithKline IACUC.
Bladder catheter surgery. Bladder catheter implantation was performed essentially as described (10, 33) . Mice were anesthetized using isoflurane (Abbott Laboratories, N. Chicago, IL) and the urinary bladder was exposed by an abdominal midline incision. A purse string suture was placed in the dome of the bladder into which a sterile, saline-filled bladder catheter (PE-10 flanged catheter tip fused to PE-50 tubing) was inserted and secured. The catheter was routed subcutaneously to the back of the neck and stored in a skin pouch. The abdominal wall and skin were sutured to close.
Cystometry. Mice were allowed to recover from surgery for 6 -10 days before cystometry. On the day of cystometry, under light isoflurane anesthesia, the end of the bladder catheter was retrieved from the skin pouch. Saline-filled polyethylene (PE-50) tubing was used to extend the externalized catheter through a mouse infusion harness (Covance, NJ).
The catheter was then connected to a pressure transducer that was inline with the syringe pump of a Small Animal Cystometry Lab Station (MED Associates, St. Albans, VT). The mice were placed in a wire bottom cage located over the balance and allowed to recover from the light anesthesia (ϳ15-30 min) before initiating the continuous intravesicular infusion of saline at 25 l/min for the duration of the study. Mice were euthanized on completion of cystometric profiling by carbon dioxide inhalation with diaphragm disruption as a secondary euthanasia method.
Drug administration. PGE 2 and glacial acetic acid were purchased from Sigma. 4-[(Phenylcarbonyl)amino]phenyl (4Z)-7-{(1R,2R,3R)- 3-hydroxy-2-[(2R)-2-hydroxy-3-(phenyloxy)propyl]oxy-5-oxocyclopentyl}-4-heptenoate (GR63799X) was synthesized in house at GlaxoSmithKline Pharmaceuticals. PGE 2 and GR63799X were dissolved in ethanol and DMSO, respectively, and diluted 1:1,000 in saline just before bladder infusion. In all studies, infusion of saline was initiated with a 30-min equilibration period that was followed by 30 min of control urodynamics. Mice were then challenged intravesicularly with various agents; GR63799X (10 M) was infused into male 129P3/J mice for 120 min, PGE 2 (120 M) was infused into female B6 mice for 120 min, and acetic acid (0.25% vol/vol) was infused into male 129P3/J mice for 60 min.
Statistics and analysis. Statistical evaluations were made by Student's paired t-test within a group, or unpaired t-test between groups of mice (GraphPad Prism). In all cases, urodynamics were assessed by analysis of the last 30 min of recording in the presence of drug, using the MED Associates analysis module in conjunction with Origin 7.0 (OriginLab, Northampton, MA). Parameters measured were infused maximum (volume infused to induce voiding), void volume (urine voided), pressure threshold (pressure before micturition), average filling pressure, and peak pressure (micturition peak). Since EP3 KO mice demonstrated larger infused and voided volumes compared with WT mice under control conditions, the response to intravesicular drug challenge was expressed as a percentage of control; the percent control values were compared between genotypes. In some cases, the effect on bladder volumes was assessed as a change from control. Nonvoiding contractions were assessed as increases in bladder pressure of greater than 5 mmHg during the filling phase and were analyzed using Mini Analysis software (Synaptosoft, Decatur, GA).
RESULTS

Comparison of EP3 WT and KO mice.
Consistent with data reported on another EP3 KO mouse (28), the male 129/P3J EP3 KO mice (8) weighed significantly more than 129/P3J WT controls (KO 30.0 Ϯ 0.5 g, n ϭ 19; WT 26.2 Ϯ 0.7 g, n ϭ 12; P Ͻ 0.0001) of equivalent age (ϳ21 wk; KO 151 Ϯ 1 days, n ϭ 19; WT 152 Ϯ 2 days, n ϭ 12; P ϭ 0.5) when maintained on a regular diet. A cystometric comparison of male EP3 WT and EP3 KO mice suggested that EP3 KO mice have an enhanced bladder capacity, based on an observation of higher voided urine volumes (191% of EP3 WT), and higher infused volumes required to stimulate micturition (181% of EP3 WT) in the EP3 KO mice (Fig. 1 ). Threshold and average filling pressures were not significantly different between genotypes; however, the peak micturition pressure was significantly higher in KO mice (Table 1) . Nonvoiding bladder contractions (pressure oscillations) as assessed during the filling phase of the cystometrigrams were not different in terms of average amplitude or frequency of these events between the two genotypes (n ϭ 8 per genotype; amplitude: WT 10.3 Ϯ 0.5 mmHg, KO 10.6 Ϯ 0.9 mmHg, P ϭ 0.77; frequency: WT 0.016 Ϯ 0.002 Hz, KO 0.021 Ϯ 0.002 Hz, P ϭ 0.13). The average age of the WT and KO mice utilized for this comparison was not significantly different; however, the EP3 KO mice weighed significantly more than the WT mice (KO 30.0 Ϯ 1 g, n ϭ 8; WT 26 Ϯ 1 g, n ϭ 8; P ϭ 0.03), as shown in general for these mice above. To compensate for the differential size of EP3 WT and KO mice, we normalized the infused and voided bladder volumes by body weight. When compensating for this weight difference, the infused and voided bladder volume/body weight ratios (l/g) were also significantly different (infused: 8 Ϯ 1 WT, 12 Ϯ 1 KO, P ϭ 0.03; void: 6 Ϯ 1 WT, 11 Ϯ 1 KO, P ϭ 0.02), indicating that the enhanced bladder capacity of the EP3 KO mice was not solely due to an increased body size.
Acetic acid-induced bladder overactivity. The same mice utilized for the basal urodynamic comparison were challenged with intravesicular infusion of acetic acid (AA; 0.25% vol/vol). AA evoked a significant decrease in infused and voided volumes and a significant increase in threshold and average filling pressures in both WT and KO mice (Table 1) . Peak micturition pressure was also increased in both the WT and KO mice. When AA urodynamic parameters were normalized to their respective controls, no significant difference in the AA response between WT and KO mice was observed (Table 1) .
EP3 receptor activation with GR63799X. Infusion of the EP3 receptor agonist GR63799X (10 M) (31) into WT mice caused a reduction in both the voided and infused bladder volumes, with no significant effect on average, threshold, and peak micturition pressures ( Fig. 2A,Table 2 ). In contrast, there was a time-dependent increase in the voided and infused volumes in vehicle-infused WT mice (n ϭ 7). Although the GR63799X response on voided and infused volumes did not reach statistical significance compared with control values in the same mice before GR63799X infusion (Table 2) 
The reduction in voided and infused bladder volumes in response to GR63799X observed in WT mice was absent in EP3 KO mice. KO mice demonstrated an increase in voided and infused bladder volumes in the presence of GR63799X (Fig. 2, Table 2 ). GR63799X treatment in KO mice resulted in ϩ86 Ϯ 42 and ϩ83 Ϯ 35 l changes in infused and voided volumes, respectively (n ϭ 9). Similar increases were observed with vehicle treatment in the KO mice (n ϭ 4). These responses in the EP3 KO were similar to the effect of vehicle treatment in WT mice, and in both genotypes likely reflect a time-dependent increase in bladder capacity resulting from the continuous infusion of saline. Overall, normalizing the GR63799X response to control demonstrated that the effect on voided and infused bladder volumes in WT mice was significantly different from that observed in KO mice (Fig. 2 , Table  2 ). No significant differences were observed between genotypes on peak micturition and average bladder pressures (Table  2) . A significant increase in threshold pressure was observed with GR63799X in KO mice. This is consistent with observations in vehicle-treated KO mice and is likely a result of the time-dependent increase in bladder capacity.
PGE 2 -induced bladder overactivity. We infused EP3 WT and EP3 KO mice with the physiological ligand for the EP3 receptor, PGE 2 . WT mice infused with 10 M PGE 2 yielded no reduction in bladder volumes (n ϭ 8). However, PGE 2 at 120 M evoked a reduction in infused and voided volumes, with no significant effect on bladder pressures (Fig. 3, Table 3 ). This concentration is considerably higher than the low nanomolar levels measured in urine from overactive bladder pa- Table 2 tients (14, 15) and spinal cord-injured rats (19) . However, it is well-known that PGE 2 is rapidly metabolized in vivo. In EP3 KO mice challenged with 120 M PGE 2 , no significant effect on infused and voided bladder volumes, peak micturition, or threshold pressures was detected (Fig. 3, Table 3 ). A significant increase in average filling pressure was detected in the EP3 KO with PGE 2 . However, when the normalized response to PGE 2 on average filling pressure was compared between WT and KO mice, no significant difference was observed between genotypes (Table 3) . In contrast, normalized data demonstrated that the response to PGE 2 on infused and voided volumes was significantly different between genotypes (Fig. 3 , Table 3 ), implying that the response to PGE 2 on infused and voided bladder volumes is dependent on the expression of the EP3 receptor gene. Vehicle treatment of EP3 WT and KO mice demonstrated no significant effect (n ϭ 5 each). A comparison between the response of WT to vehicle or PGE 2 treatment yielded a significant difference between vehicle and PGE 2 on void and infused volumes (Fig. 3, C and D) . In KO mice, no significant difference was observed between vehicle and PGE 2 . However, the KO mice treated with PGE 2 presented a trend toward both a reduction in void and infused volumes with PGE 2 relative to vehicle, suggesting a residual response to PGE 2 in the EP3 KO.
. Effect of intravesicular GR63799 (10 M) on EP3 WT and EP3 KO bladder pressures (mmHg) and volumes (l)
Infused
DISCUSSION
To our knowledge, this is the first study implicating a role for EP3 receptors in the regulation of urinary bladder function/ dysfunction. We demonstrated that EP3 receptor KO mice present with an enhanced bladder capacity, based on the detection of higher infused and voided bladder volumes compared with WT controls. In addition, WT mice demonstrate bladder overactivity (a reduction in voided and infused volumes) evoked by activation of EP3 receptors with intravesicular infusion of the EP3 agonist GR63799X, an effect that is absent in EP3 KO mice. Together, these data provide genetic and pharmacological evidence supporting the ability of EP3 receptors to modulate bladder function. Both preclinical and clinical studies link an enhancement of PGE 2 production (the physiological ligand for the EP3 receptor) to urinary bladder overactivity (11, 14, 15, 24, 25) . Consistent with this concept, WT mice infused with PGE 2 developed bladder overactivity, while EP3 KO mice presented no significant response to PGE 2 . These data further implicate EP3 not only as playing a role in normal bladder function, but also in the pathophysiology of bladder overactivity.
The enhanced bladder capacity in age-matched EP3 KO mice reported here is not due to the larger size of the EP3 KO mice (28 and confirmed in this study), as normalizing both the infused and voided volumes to mouse weight concluded that EP3 KO mice also have significantly enhanced voided and infused bladder volumes per gram body weight. EP3 is expressed in the kidney, playing a role in the regulation of urine production and urine osmolality (9) . However, the enhanced bladder capacity in EP3 KO mice is not due to compensatory changes resulting from alterations in urine production because under basal conditions, urine production and osmolality are unaltered in the EP3 KO (8) . Taken together, this suggests that the enhanced bladder capacity observed in EP3 KO mice results from the loss of EP3 receptor activity in mechanisms controlling bladder function. EP3 KO mice also demonstrated a larger peak micturition pressure than the WT controls. The rationale for this difference in peak pressure is unknown, but conceivably could result from the larger bladder capacity in the EP3 KO requiring a heightened micturition pressure to effectively void the larger volume held by the EP3 KO bladders. Alternatively, the EP3 KO may have an enhanced urethral resistance during micturition, due to EP3-dependent changes in the regulation of urethral contractility, thereby increasing the bladder pressure during voiding. This is supported by the reported ability of PGE 2 to decrease urethral pressure during micturition (13) .
Our results demonstrating a significant alteration in basal bladder function in EP3 KO mice are in contrast to the lack of difference in basal urodynamics reported for EP1 KO mice (29) . This suggests that EP3 receptors play a prominent role in basal urodynamics under normal conditions, while EP1 receptors do not. Although, acute pharmacological manipulation with antagonists targeting the EP1 receptor suggests EP1 receptor activity may be involved in normal rat bladder function (16, 18) . Interestingly, the markedly reduced response to PGE 2 infusion in EP3 KO mice on bladder volumes reported here is similar to that reported for EP1 KO mice (29) . In the current study, EP3 WT mice demonstrated a significantly larger reduction in bladder volumes in response to PGE 2 than EP3 KO mice implicating EP3 as a key player in PGE 2 -induced bladder overactivity. Although there was no significant response to PGE 2 on bladder volumes in EP3 KO mice (as compared with control values in the same mice, or vehicletreated KO mice), the difference between vehicle-and PGE 2 -treated EP3 KO mice suggests part of the responsiveness to PGE 2 may remain in the EP3 KO. This residual response to PGE 2 on bladder volumes in the EP3 KO may represent an EP1 component as described in EP1 KO mice (29) . Taken together, the current study and Schröder et al. (29) suggest a role for both EP3 and EP1 receptors under conditions of PGE 2 -induced bladder overactivity, as observed in preclinical models and in overactive bladder patients (11, 14, 15, 24, 25) .
The reductions in voided and infused bladder volumes with the EP3 selective agonist GR63799X in WT mice are lost in the EP3 KO, indicating that GR63799X-induced bladder overactivity in WT mice is mediated selectively through the EP3 receptor. EP3 KO mice demonstrated an increase in voided and infused bladder volumes in the presence of GR63799X. This (17, 21) . Here, we show that EP3 KO mice have a reduced response to PGE 2 , but an unaltered response to AA. This indicates that EP3 plays a major role in the response to PGE 2 and a minimal role, if any, in the response to AA. Even though in both cases bladder overactivity is mediated via afferent nerves, AA-induced bladder overactivity is likely to involve other mechanisms besides PGE 2 production. In contrast, PGE 2 is established as a selective agonist of EP receptors. This is supported by the loss in functional response to PGE 2 and the lack of a detectable alteration in the response to AA in the EP3 KO. Therefore, the increased bladder capacity in EP3 KO mice, and bladder overactivity induced by EP3 activation, may involve a reduction and an enhancement, respectively, of the sensitivity of bladder afferents. Alternatively, or in addition to an expression of EP3 on afferent nerves, EP3 may be expressed on other cell types within the bladder (i.e., urothelial or smooth muscle cells) where its activity could modulate bladder activity. Further studies to localize the expression of EP3 receptors in the bladder and in bladder-associated nerves will be required to unravel the mechanisms involved in the in vivo responses described here. We can also not eliminate a role for CNS/ spinal-based functional expression of EP3 receptors in the phenotype presented by the EP3 KO mice, as reported for EP3-mediated PGE 2 -induced pain responses (20) . Here, we provide the first description of the role of EP3 receptors in regulating urinary bladder function, with EP3 receptors contributing to normal bladder function, and acting as a pathophysiological mediator of bladder dysfunction under conditions of enhanced PGE 2 production as observed in overactive bladder patients. EP3 receptor antagonists are therefore likely to provide efficacy in preclinical models of bladder overactivity and in overactive bladder patients without the gastrointestinal side effects coincident with COX inhibitors.
